BUSINESS● LOW1h ago · Sep 8, 2026, 8:33 AM
Upstream Bio stock jumps 8% on Phase 2 severe asthma data
Seeking Alpha Tech · global
Upstream Bio's stock increased by 8% following the release of Phase 2 data related to severe asthma treatment. This indicates a positive market reaction to the clinical trial results.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS35m agoBiggest stock movers Tuesday: ZIM, NVS, and moreSeeking Alpha TechBUSINESS40m agoThe yen's sudden surge upsets the carry trade faithfulYahoo FinanceBUSINESS40m agoPhilippines wants to be a global semiconductor giant by 2030. Can it get there?South China Morning PostBUSINESS42m agoTrump threatens ban on Bombardier as Canada's retaliatory tariffs kick inFrance 24 [en]